Nabumetone - A New Nsaid
Nabumetone (Relafen - SmithKline Beecham), a new nonsteroidal anti-inflammatory drug (NSAID), has been approved by the US Food and Drug Administration for treatment of rheumatoid arthritis and osteoarthritis. The drug has been available in the United Kingdom since 1987. The manufacturer claims that nabumetone is as effective as other NSAIDs and causes a relatively low incidence of peptic ulcers....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Nabumetone - A New Nsaid
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 868
Article Code: 868b
Date: April 17, 1992
Volume: 34
Pages: 38-40
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 868
Article Code: 868b
Date: April 17, 1992
Volume: 34
Pages: 38-40
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)